• Lifestyle modifications and their impact on AFib treatment
• Common co-morbidities associated with AFib
• Appropriate anticoagulation strategies
• Non-pharmacological therapies for stroke prevention
• Open to more if necessary

What to Expect:

This Townhall meeting is designed to be an interactive and engaging forum where healthcare professionals can explore and discuss key aspects of AFib management. The session will include:

• Panel Discussion: The session will open with a panel of experts who will provide insights into the latest research and guidelines on risk factor modification, prevention, and stroke prevention in AFib, following up on the webinars that have been produced (30min including intros).
• Submitted Questions: To ensure the discussion is relevant and tailored to the audience's needs, we will be collecting questions from participants prior to the Townhall. These questions will be used to guide the panel discussion and ensure that key concerns and topics of interest are addressed.
• Audience Participation: In addition to pre-submitted questions, there will be opportunities for live audience participation. Attendees will be encouraged to submit questions during the Townhall, which will be moderated by HRS staff, allowing for real-time interaction and engagement with the panelists.

Peter A. Noseworthy, MD, FHRS| Mayo Clinic
Research: National Institutes for Heath, National Institute on Aging, Agency for Healthcare Research and Quality, U.S. Food & Drug Administration, American Heart Association, Medtronic Inc. 
Honoraria/Speaking/Consulting Fee: Optum
Royalty Income: Alivecor

Janice Y. Chyou, MD, FHRS| Icahn School of Medicine at Mount Sinai
Honoraria/Speaking/Consulting Fee: American Heart Association, McGraw –Hill, Medtronic Inc.
Research: American Heart Association

Rakesh Gopinathannair, MA, MD, FHRS
Honoraria/Speaking/Consulting: Abbott
Membership on Advisory Committees/Committee Officer: AltaThera Pharmaceuticals, Heart Rhythm Society, Pacemate

ACE Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.

Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.

ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

• Advertising, marketing, or communication firms whose clients are ineligible companies
• Bio-medical startups that have begun a governmental regulatory approval process
• Compounding pharmacies that manufacture proprietary compounds
• Device manufacturers or distributors
• Diagnostic labs that sell proprietary products
• Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
• Manufacturers of health-related wearable products
• Pharmaceutical companies or distributors
• Pharmacy benefit managers
• Reagent manufacturers or sellers